Expertise in
11
conditions

Dr. Rachel B. Salit

Hematology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
22 Years of Experience
Expertise in
11
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Rachel Salit is a Hematologist practicing medicine in Seattle, Washington. She has been practicing medicine for over 22 years.

Dr. Salit is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myelodysplastic Syndrome (MDS), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 7 clinical trials. Dr. Salit is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WA

Languages Spoken

English
German
Mandarin
Vietnamese

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Community Health
  • EPO
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis
Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis
Enrollment Status: Recruiting
Publish Date: July 20, 2026
Intervention Type: Radiation, Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 2
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus
Study Phase: Phase 2
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
Enrollment Status: Completed
Publish Date: March 30, 2026
Intervention Type: Drug, Radiation, Other, Procedure
Study Drugs: Busulfan, Cyclophosphamide, Fludarabine Phosphate, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus
Study Phase: Phase 2
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Terminated
Publish Date: January 23, 2023
Intervention Type: Drug, Biological, Radiation, Procedure
Study Drugs: Cyclophosphamide, Filgrastim, Fludarabine, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 2
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Enrollment Status: Completed
Publish Date: December 27, 2019
Intervention Type: Drug, Radiation, Other, Procedure
Study Phase: Phase 2
View 4 Less Clinical Trials

68 Total Publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Farsi, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mazyar Shadman is a Hematologist practicing medicine in Seattle, Washington. Dr. Shadman is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Shadman is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
855-557-0555
Languages Spoken:
English, German, Portuguese, Russian, Ukrainian
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrei Shustov is a Hematologist practicing medicine in Seattle, Washington. Dr. Shustov is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shustov is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-606-1955
Languages Spoken:
English, Hindi, Nepali, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Chaitra Ujjani is a Hematologist practicing medicine in Seattle, Washington. Dr. Ujjani is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ujjani is currently accepting new patients.

Frequently Asked Questions about Dr. Rachel B. Salit

How do I make an appointment with Dr. Rachel B. Salit?

You can book an appointment with Dr. Rachel B. Salit by calling their office at 206-667-1317. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rachel B. Salit a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rachel B. Salit is classified as an Elite expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rachel B. Salit specialize in?

While Dr. Rachel B. Salit is a Hematology, they have specific expertise in Myelofibrosis, Myelodysplastic Syndrome (MDS), and Chronic Graft Versus Host Disease (cGvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rachel B. Salit participate in research or clinical trials?

Yes. Dr. Rachel B. Salit has published 68 articles and abstracts on conditions like Myelofibrosis. You can view a list of Dr. Rachel B. Salit's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rachel B. Salit accept my insurance?

Dr. Rachel B. Salit accepts most major insurance plans, including Community Health and Humana. We recommend calling the office directly at 206-667-1317 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Salit's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile